JP2018172409A5 - 15−hepeを含む組成物および同組成物を使用する方法 - Google Patents

15−hepeを含む組成物および同組成物を使用する方法 Download PDF

Info

Publication number
JP2018172409A5
JP2018172409A5 JP2018121494A JP2018121494A JP2018172409A5 JP 2018172409 A5 JP2018172409 A5 JP 2018172409A5 JP 2018121494 A JP2018121494 A JP 2018121494A JP 2018121494 A JP2018121494 A JP 2018121494A JP 2018172409 A5 JP2018172409 A5 JP 2018172409A5
Authority
JP
Japan
Prior art keywords
hepe
compositions
methods
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018121494A
Other languages
English (en)
Other versions
JP2018172409A (ja
Filing date
Publication date
Priority claimed from GBGB1301626.6A external-priority patent/GB201301626D0/en
Application filed filed Critical
Publication of JP2018172409A publication Critical patent/JP2018172409A/ja
Publication of JP2018172409A5 publication Critical patent/JP2018172409A5/ja
Pending legal-status Critical Current

Links

JP2018121494A 2013-01-30 2018-06-27 15−ohepaを含む組成物および同組成物を使用する方法 Pending JP2018172409A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1301626.6A GB201301626D0 (en) 2013-01-30 2013-01-30 Composition comprising 15-OHEPA and methods of using the same
GB1301626.6 2013-01-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015555661A Division JP6363104B2 (ja) 2013-01-30 2014-01-24 15−ohepaを含む組成物および同組成物を使用する方法

Publications (2)

Publication Number Publication Date
JP2018172409A JP2018172409A (ja) 2018-11-08
JP2018172409A5 true JP2018172409A5 (ja) 2019-05-16

Family

ID=47891001

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015555661A Expired - Fee Related JP6363104B2 (ja) 2013-01-30 2014-01-24 15−ohepaを含む組成物および同組成物を使用する方法
JP2018121494A Pending JP2018172409A (ja) 2013-01-30 2018-06-27 15−ohepaを含む組成物および同組成物を使用する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015555661A Expired - Fee Related JP6363104B2 (ja) 2013-01-30 2014-01-24 15−ohepaを含む組成物および同組成物を使用する方法

Country Status (28)

Country Link
US (5) US20150224076A1 (ja)
EP (2) EP2762143B1 (ja)
JP (2) JP6363104B2 (ja)
KR (5) KR102274963B1 (ja)
CN (2) CN105120872B (ja)
AU (2) AU2014211628B2 (ja)
BR (1) BR112015018270A2 (ja)
CA (1) CA2897343C (ja)
CY (1) CY1117209T1 (ja)
DK (1) DK2762143T3 (ja)
ES (2) ES2564025T3 (ja)
GB (1) GB201301626D0 (ja)
HK (1) HK1200351A1 (ja)
HR (1) HRP20160203T1 (ja)
HU (1) HUE026901T2 (ja)
IL (3) IL239893A (ja)
MX (2) MX364646B (ja)
NZ (1) NZ709803A (ja)
PH (1) PH12015501582A1 (ja)
PL (1) PL2762143T3 (ja)
PT (1) PT2762143E (ja)
RS (1) RS54584B1 (ja)
RU (2) RU2671208C2 (ja)
SG (2) SG10201806854XA (ja)
SI (1) SI2762143T1 (ja)
SM (1) SMT201600069B (ja)
WO (1) WO2014118097A1 (ja)
ZA (2) ZA201505018B (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
JP2016538288A (ja) 2013-11-15 2016-12-08 ディグニティ サイエンシス リミテッド 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
WO2015106215A2 (en) * 2014-01-10 2015-07-16 Mehar Manku Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
EP3247348A1 (en) * 2015-01-16 2017-11-29 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
US20180104201A1 (en) 2015-04-28 2018-04-19 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and or treating non alcoholic steatohepatitis
CN117402059A (zh) * 2015-05-13 2024-01-16 Ds生物制药有限公司 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
CN112245420A (zh) * 2015-07-21 2021-01-22 艾菲穆恩有限公司 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物
MX2018007390A (es) 2015-12-18 2018-11-09 Afimmune Ltd Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
KR20200096791A (ko) 2017-12-06 2020-08-13 바스프 에이에스 비알콜성 지방간염 치료용 지방산 유도체
CN115215725A (zh) * 2021-04-15 2022-10-21 宋晓瑜 一种制备乙酸薰衣草酯及薰衣草醇的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
AU673700B2 (en) 1993-01-27 1996-11-21 Scotia Holdings Plc Triglycerides
CA2149653C (en) 1993-10-01 1999-02-23 Frank S. S. Morton Methods and compositions for dispensing fragrances
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
DE60124256T3 (de) 2000-02-16 2012-09-20 The Brigham And Women's Hospital Inc. Aspirin-ausgelöste lipidmediatoren
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
HUP0401343A3 (en) 2001-05-30 2008-08-28 Laxdale Ltd Compositions containing coenzyme q and eicosapentaenoic acid (epa) and their use
CN1250230C (zh) * 2001-09-30 2006-04-12 中国药品生物制品检定所 海狗油作为制备治脂肪肝药的应用
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
EP1711173A2 (en) 2003-12-31 2006-10-18 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof
WO2005102309A2 (en) 2004-04-26 2005-11-03 Ltb4 Sweden Ab In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
CA2572344A1 (en) 2004-07-01 2006-01-19 Schepens Eye Research Compositions and methods for treating eye disorders and conditions
EP1973536A2 (en) * 2006-01-05 2008-10-01 Reliant Pharmaceuticals, Inc. Treatment of fatty liver
BRPI0715402A2 (pt) 2006-08-08 2013-11-26 Lipomics Technologies Inc Marcadores de doença hepática gordurosa não alcoólica (nafld) e esteatohepatite não alcoólica (nash) e métodos de uso dos mesmos
US20100120914A1 (en) * 2007-03-30 2010-05-13 Kowa Company, Ltd. Medicament for prophylactic and/or therapeutic treatment of hepatic steatosis or non-alcoholic steatohepatitis
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
JPWO2009154230A1 (ja) * 2008-06-17 2011-12-01 持田製薬株式会社 非アルコール性脂肪肝炎の予防/改善・治療薬
WO2010095706A1 (ja) * 2009-02-20 2010-08-26 国立大学法人東京大学 新規抗炎症性化合物
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
US9238634B2 (en) * 2010-08-19 2016-01-19 The University Of Tokyo Anti-inflammatory metabolite derived from omega-3-type fatty acid
WO2012031125A2 (en) 2010-09-01 2012-03-08 The General Hospital Corporation Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
US10154977B2 (en) 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US8936803B2 (en) 2011-10-19 2015-01-20 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
CA2856715A1 (en) 2011-11-29 2013-06-06 Dignity Sciences Limited Compositions comprising 20-carbon fatty acids and methods of making and using same
US20150004224A1 (en) 2012-01-06 2015-01-01 Omthera Phrmaceuticals, Inc. Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
AU2013259503B2 (en) * 2012-05-10 2017-03-16 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
MX2018007390A (es) 2015-12-18 2018-11-09 Afimmune Ltd Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.

Similar Documents

Publication Publication Date Title
JP2018172409A5 (ja) 15−hepeを含む組成物および同組成物を使用する方法
DK3595653T3 (da) Sammensætninger af plinabulin og anvendelse heraf
GB2582482B (en) CASZ compositions and methods of use
DK3559009T3 (da) Sammensætninger og metoder til inhibition af arginaseaktivitet
MA50205A (fr) Formulation de nicotine
DK3478811T3 (da) Rengøringssammensætninger og anvendelser deraf
MA46481A (fr) Compositions d'oligonucléotides et méthodes associées
DK3557998T3 (da) Sammensætninger, kompositioner og anvendelsesmetoder
GB2582100B (en) CAS12C Compositions and methods of use
EP3576782A4 (en) COMPOSITIONS OF RECOMBINATION PRODUCT-PEPTIDE AND THEIR METHODS OF USE
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
MA47611A (fr) Compositionset méthodes de transduction tumorale
DK3606929T3 (da) Beta-nicotinat-ester-nukleotider og fremgangsmåder til fremstilling af samme
ZA202100780B (en) Bismuth-thiol compositions and methods of use
MA54143A (fr) Compositions et méthodes
IL276135A (en) Preparations and methods of use
ZA201906169B (en) Synthekine compositions and methods of use
KR20220035877A (ko) Cd33 변형을 위한 조성물 및 방법
IL283968A (en) Benzamides of pyrazole-amino-pyrimidine type substances and their use
DK3288379T3 (da) Peptidsammensætninger og anvendelsesmåder
DK3398598T3 (da) Sulfonamidderivat og fremstillingsmetode og anvendelse deraf
SG11202011274YA (en) Chemical compositions and methods of using same
EP3574047A4 (en) EMULSION COMPOSITIONS AND METHOD FOR USE THEREOF
GB2568562B (en) Moldable compositions and methods of using thereof
DK3678644T3 (da) Formuleringer af copanlisib